Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8092616 | 0.83 | GRM7 (0.50) | GRIN2BSIGMAR1NPY1RPRMT5GRM7 | |
| SCHEMBL23095824 | 0.83 | GRIN2B (0.54) | GRIN2BSIGMAR1NPY1RPRMT5MAOA | |
| SCHEMBL23095755 | 0.80 | NPY1R (0.56) | NPY1RPRMT5 | |
| SCHEMBL4859978 | 0.78 | GRIN2B (0.55) | GRIN2BSIGMAR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL1026811 | 0.77 | GRIN2B (0.53) | GRIN2BSIGMAR1MAOAMAOB | |
| SCHEMBL17560147 | 0.76 | NPY1R (0.56) | NPY1RPRMT5 | |
| SCHEMBL12656184 | 0.76 | KDM4E (0.59) | GRIN2BNPY1RPRMT5 | |
| SCHEMBL17560157 | 0.76 | NPY1R (0.56) | NPY1RPRMT5 | |
| SCHEMBL17572160 | 0.76 | NPY1R (0.56) | NPY1RPRMT5 | |
| SCHEMBL1792787 | 0.75 | GRIN2B (0.61) | GRIN2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| WO-2020247860-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-1819686-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006056471-A1 | 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ALKBH3 | GRIN2B 4620/4885SIGMAR1 4276/4885NPY1R 3603/4885 |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | GRIN2B 3161/4885SIGMAR1 418/4885NPY1R 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.